MGNX insider trading
NasdaqGS HealthcareMACROGENICS INC: insider trade history from SEC Form 4 filings.
About MACROGENICS INC
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Company website: www.macrogenics.com
MGNX insider activity at a glance
FilingIQ tracks 394 insider transactions for MGNX in filings since Feb 3, 2015. The most recent transaction is dated Aug 19, 2026.
Across the full history, 24 open-market purchases
and 101 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MGNX insider trades is 47.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MGNX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for MGNX?
- FilingIQ tracks 394 Form 4 insider transactions for MGNX (MACROGENICS INC), covering filings from Feb 3, 2015 onwards. 2 of those are dated within the last 90 days.
- Are MGNX insiders net buyers or net sellers?
- Across the full Form 4 history for MGNX, 24 transactions (6%) were open-market purchases and 101 (26%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MGNX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is MGNX in?
- MACROGENICS INC (MGNX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $103.74M.
Methodology & sources
Every MGNX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.